Blood-spinal cord barrier junction proteins (BSCB junction proteins)

Blood-spinal cord barrier (BSCB) junction proteins are a specialized group of proteins, including claudins (notably Claudin-5), occludin, and zonula occludens-1 (ZO-1), that form the physical seal between endothelial cells in the spinal cord vasculature (Bartanusz et al., 2011). These proteins are critical for maintaining the unique microenvironment required for neuronal signaling by strictly regulating the paracellular movement of ions, molecules, and cells from the blood into the spinal cord parenchyma (Lee et al., 2012). In conditions such as spinal cord injury (SCI), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS), the expression and localization of these proteins are often disrupted, leading to barrier hyperpermeability, edema, and neuroinflammation (Winkler et al., 2014). Therapeutic strategies targeting these proteins aim to restore barrier integrity, often by inhibiting degradative enzymes like matrix metalloproteinases (MMPs) or using hormonal and anti-inflammatory agents to upregulate junctional protein expression (UniProt O00501). Drugs such as methylprednisolone and progesterone have been shown to stabilize these junctions, thereby reducing secondary damage following acute injury (Labombarda et al., 2015). Understanding the specific molecular composition of the BSCB compared to the blood-brain barrier is essential for developing targeted treatments for spinal cord-specific pathologies.

Other names

BSCB proteinsTight junction proteins of the blood-spinal cord barrierAdherens junction proteins of the blood-spinal cord barrierSpinal cord endothelial junction proteins

Stabilization of tight and adherens junction complexes, inhibition of matrix metalloproteinase-mediated degradation, and reduction of endothelial permeability (Lee et al., 2012; Bartanusz et al., 2011).